Paul Wotton

Paul Kevin Wotton is the founder of Avenge Bio, Inc. Current roles include CEO, Director & Managing Partner at RBL LLC since 2024; Independent Director at Vericel Corp.
since 2015; Director at eXIthera Pharmaceuticals, Inc.; Independent Non-Executive Director at Cynata Therapeutics Ltd. since 2020; Director at Combined Therapeutics, Inc. since 2023; Independent Director at Dimension Inx LLC since 2023; Member of the Royal Pharmaceutical Society of Great Britain; and Member of the Licensing Executives Society.
Former positions include President, Chief Executive Officer & Director at Antares Pharma, Inc. from 2011 to 2014; President, Chief Executive Officer & Director at Astellas Institute for Regenerative Medicine from 2014 to 2016; President, Chief Executive Officer & Director at Obsidian Therapeutics, Inc. from 2019 to 2022; Chief Executive Officer at Topigen Pharmaceuticals, Inc. from 2004 to 2008; Independent Chairman at Kytopen Corp.
from 2023 to 2025; Co-Chairman-Integration Management Office at Astellas Pharma US, Inc. in 2016; Director at Genaera Corp.
from 2008 to 2009; Independent Director at Veloxis Pharmaceuticals A from 2016 to 2020; Independent Director at PaxMedica, Inc. from 2020 to 2021; Director at Sigilon Therapeutics, Inc. from 2018 to 2019; Head-Global Business Development at SkyePharma Plc from 2002 to 2004; Director at BIOTECanada; Director at Cadent Therapeutics, Inc.; Vice President-Business Development at Penwest Pharmaceuticals Co.; Vice President-Corporate Development at Eurand NV; and Operations Manager at Kelyniam Global, Inc. Education includes undergraduate studies at the University of London, a doctorate from The University of Nottingham, and an MBA from Kingston Business School.